Business
Half-year Report
Genflow Biosciences PLC announced its half-year results for the six months ended 30 June 2025. The Group's cash reserves marginally increased to £279,445 from £278,682 at the end of 2024, supported by equity fundraising of £868,698 net of expenses during the first half of 2025. Administration expenses totaled £982,725, including research and development costs of £665,862, legal and professional fees of £156,094, and Directors' fees of £55,272. The company reported a loss for the period of £737,618, and a basic loss per share of (0.192) pence. Other Comprehensive Income included a translation loss of £31,075. As of June 30, 2025, the Group is in a net liability position totaling £303,003. The company issued 103,841,324 new shares during the period. Disclaimer*
About this update from Genflow Biosciences Plc
[{"type":"text","content":"\n\nPRESS RELEASE\n \n30 September 2025\nGenflow Biosciences Plc\n \n(\"Genflow\" or \"the Company\")\n \nHALF YEAR RESULTS\n \nGenflow (LSE: GENF) (OTCQB:GENFF) is pleased to announce its half year results for the six-month period ended 30 June 2025.\n \nChairman's Statement\n \nIt is my pleasure to update shareholders of Genflow Biosciences Plc (\"Genflow\" or the \"Company\") on our performance during the first six months of 2025.\n \nAs of 30 June 2025, Genflow has made important progress across its programs in both human health and animal health, advancing our mission to extend healthspan through our proprietary SIRT6 centenarian-based gene therapies. These two dimensions of our pipeline are deeply complementary: our human programs target age-related diseases with high unmet need, while our veterinary initiatives allow us to generate translational data, demonstrate safety and feasibility, and explore commercial opportunities in the growing companion animal health sector.\n \nHuman Health Pipeline\n \nIn human health, our pipeline spans MASH (\"Metabolic Dysfunction-Associated Steatohepatitis\"), sarcopenia, Werner Syndrome, and exploratory programs in ophthalmology. Collectively, these programs highlight the versatility of SIRT6 centenarian in addressing fundamental mechanisms of aging across multiple systems.\n \nThe most notable development has been in MASH. Recent approvals of two new therapies including GLP-1 agonists have provided effective therapies for patients in the earlier stages of disease (approximately two-thirds of the population). However, there remains a profound unmet need in advanced MASH with fibrosis, where therapeutic options are extremely limited. In response, Genflow has repositioned GF-1002 to target this high-need population (around one-third of patients). With its antifibrotic properties and potential to prevent progression to liver cancer, GF-1002 is uniquely suited to address this stage of disease. While the patient population is smaller, the commercial opportunity is significant, given the lack of alternatives beyond liver transplantation.\n \nIn parallel, we are expanding into ophthalmology, where SIRT6-based therapies hold promise in corneal pathologies and glaucoma. Current glaucoma treatments focus primarily on reducing intraocular press...